Health Catalyst, Inc. (NASDAQ:HCAT) Director Sells $31,410.00 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) Director Duncan Gallagher sold 4,500 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $6.98, for a total value of $31,410.00. Following the completion of the sale, the director now directly owns 74,438 shares of the company’s stock, valued at $519,577.24. This trade represents a 5.70 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Health Catalyst Stock Performance

Shares of HCAT opened at $7.08 on Monday. The stock has a 50 day moving average of $7.96 and a 200 day moving average of $7.48. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst, Inc. has a 12 month low of $5.42 and a 12 month high of $11.41. The company has a market capitalization of $430.80 million, a price-to-earnings ratio of -5.24 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.22) earnings per share. As a group, sell-side analysts forecast that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Institutional Trading of Health Catalyst

Several hedge funds have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. grew its position in shares of Health Catalyst by 6.9% during the 2nd quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after acquiring an additional 1,907 shares during the period. Harbor Capital Advisors Inc. grew its holdings in Health Catalyst by 21.3% during the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after purchasing an additional 2,064 shares during the period. The Manufacturers Life Insurance Company increased its position in Health Catalyst by 10.3% in the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock worth $148,000 after buying an additional 2,164 shares during the last quarter. Creative Planning increased its position in Health Catalyst by 13.2% in the third quarter. Creative Planning now owns 21,348 shares of the company’s stock worth $174,000 after buying an additional 2,486 shares during the last quarter. Finally, Quarry LP raised its stake in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after buying an additional 2,610 shares during the period. Institutional investors own 85.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Stephens boosted their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 14th. Evercore ISI raised their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Royal Bank of Canada lifted their price target on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Finally, Piper Sandler reissued an “overweight” rating and issued a $12.00 price objective (up from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Health Catalyst currently has a consensus rating of “Moderate Buy” and an average target price of $11.79.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.